Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.8 CAD -3.74% Market Closed
Market Cap: 146.9m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note

Cardiol Therapeutics Inc
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cardiol Therapeutics Inc
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Total Liabilities
CA$7.1m
CAGR 3-Years
39%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Total Liabilities
CA$722.7m
CAGR 3-Years
-31%
CAGR 5-Years
-24%
CAGR 10-Years
79%
Sundial Growers Inc
NASDAQ:SNDL
Total Liabilities
CA$261.1m
CAGR 3-Years
107%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Total Liabilities
$102.6m
CAGR 3-Years
11%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Total Liabilities
$57.6m
CAGR 3-Years
66%
CAGR 5-Years
210%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Total Liabilities
$2.1B
CAGR 3-Years
30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
146.9m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Total Liabilities?
Total Liabilities
7.1m CAD

Based on the financial report for Sep 30, 2024, Cardiol Therapeutics Inc's Total Liabilities amounts to 7.1m CAD.

What is Cardiol Therapeutics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
34%

Over the last year, the Total Liabilities growth was -13%. The average annual Total Liabilities growth rates for Cardiol Therapeutics Inc have been 39% over the past three years , 34% over the past five years .

Back to Top